XIAP and breast carcinoma: Furthermore, XIAP induces resistance to tyrosine kinase inhibitors such as Lapatinib in breast cancer (Aird et al., 2010), and Imatinib in acute myeloid leukemia (AML) (Silva et al., 2013).